Swedbank AB Purchases 168,857 Shares of Johnson & Johnson $JNJ

Swedbank AB raised its position in Johnson & Johnson (NYSE:JNJ) by 8.4% in the third quarter, HoldingsChannel.com reports. The fund owned 2,177,506 shares of the company’s stock after purchasing an additional 168,857 shares during the quarter. Swedbank AB’s holdings in Johnson & Johnson were worth $403,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Lifestyle Asset Management Inc. lifted its stake in Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares during the last quarter. Wynn Capital LLC raised its stake in Johnson & Johnson by 0.4% in the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after buying an additional 57 shares during the period. Defined Financial Planning LLC lifted its position in shares of Johnson & Johnson by 3.0% in the third quarter. Defined Financial Planning LLC now owns 1,926 shares of the company’s stock valued at $365,000 after buying an additional 57 shares during the last quarter. W.H. Cornerstone Investments Inc. boosted its stake in shares of Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after acquiring an additional 58 shares during the period. Finally, YANKCOM Partnership increased its holdings in shares of Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after acquiring an additional 58 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $208.01 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company’s 50 day moving average price is $199.39 and its two-hundred day moving average price is $180.50. The firm has a market cap of $501.14 billion, a PE ratio of 20.08, a PEG ratio of 2.25 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Citigroup raised their price target on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Royal Bank Of Canada set a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 17th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $210.25.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.